US20010031479A1 - Method and reagent for determination of cholesterol in remant-like particles - Google Patents

Method and reagent for determination of cholesterol in remant-like particles Download PDF

Info

Publication number
US20010031479A1
US20010031479A1 US09/788,393 US78839301A US2001031479A1 US 20010031479 A1 US20010031479 A1 US 20010031479A1 US 78839301 A US78839301 A US 78839301A US 2001031479 A1 US2001031479 A1 US 2001031479A1
Authority
US
United States
Prior art keywords
cholesterol
phospholipase
reagent
surfactant
polyoxyethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/788,393
Other languages
English (en)
Inventor
Kazuhito Miyauchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hitachi Chemical Diagnostics Systems Co Ltd
Original Assignee
Kyowa Medex Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Medex Co Ltd filed Critical Kyowa Medex Co Ltd
Assigned to KYOWA MEDEX CO., LTD. reassignment KYOWA MEDEX CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MIYAUCHI, KAZUHITO
Publication of US20010031479A1 publication Critical patent/US20010031479A1/en
Priority to US10/430,231 priority Critical patent/US7202047B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol

Definitions

  • the present invention relates to a method and a reagent for the quantitative determination of cholesterol in remnant-like particles which is considered as a risk factor for arteriosclerosis and other diseases in clinical tests.
  • cholesterol in high density lipoprotein (HDL) is considered as a negative risk factor for arteriosclerosis and cholesterol in low density lipoprotein (LDL) is considered as a positive risk factor for arteriosclerosis.
  • LDL low density lipoprotein
  • the determination of cholesterol of such classes is frequently performed in the field of clinical testing.
  • cholesterol in lipoproteins formed by lipid metabolism and the like is a more closely linked risk factor for arteriosclerosis than LDL cholesterol.
  • Such lipoproteins include remnant-like particles, and the determination of cholesterol in remnant-like particles is given health insurance scores by the Ministry of Health, Labour and Welfare in Japan.
  • a method for the determination of cholesterol in remnant-like particles, a method is known which comprises separating remnant-like particles from a sample using anti apolipoprotein B100 antibody and anti apolipoprotein A1 antibody, and measuring cholesterol in the separated remnant-like particles [Arteriosclerosis (Domyakukoka), 25 (9, 10), 371 (1998)].
  • this method employs affinity chromatography using antibodies and requires separation of components of a sample, which makes it a cumbersome and time-consuming method.
  • An object of the present invention is to provide a method and a reagent for the simple and sensitive determination of cholesterol in remnant-like particles without the separation of components of a sample.
  • the present inventor has found that in the determination of cholesterol in a biological sample containing lipoproteins such as HDL, LDL, chylomicrons (CM), very low density lipoprotein (VLDL), CM remnant, VLDL remnant and intermediate density lipoprotein (IDL) by using cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase, cholesterol in remnant-like particles (e.g., CM remnant, VLDL remnant and IDL remnant) can be specifically determined by additionally using phospholipase.
  • CM remnant, VLDL remnant and IDL remnant can be specifically determined by additionally using phospholipase.
  • the present invention has been completed based on this finding.
  • the present invention relates to the following (1)-(18).
  • a method for the quantitative determination of cholesterol in remnant-like particles in a biological sample which comprises contacting the biological sample with (i) cholesterol esterase, (ii) cholesterol oxidase or cholesterol dehydrogenase, and (iii) phospholipase in an aqueous medium in the presence of oxygen or an oxidized coenzyme, and measuring the formed hydrogen peroxide or reduced coenzyme.
  • polyoxyalkylene derivative is polyoxyethylene alkyl ether, polyoxyethylenestyrenated phenyl ether or polyoxyethylene long-chain branched alkyl ether.
  • a reagent for the quantitative determination of cholesterol in remnant-like particles comprising (i) cholesterol esterase, (ii) cholesterol oxidase or cholesterol dehydrogenase, and (iii) phospholipase.
  • the reagent according to (11) which comprises a first reagent comprising the surfactant and a second reagent comprising (i) cholesterol esterase, (ii) cholesterol oxidase or cholesterol dehydrogenase, and (iii) phospholipase.
  • FIG. 1 is a graph showing the correlation between the cholesterol concentrations (mg/dl) determined using the reagents of Example 1 (ordinate) and those determined using the RLP-C determination kit of Japan Antibody Institute (abscissa).
  • the reaction for the determination of cholesterol in remnant-like particles according to the present invention is carried out in an aqueous medium, preferably in a buffer solution.
  • Buffers useful in the buffer solution include tris(hydroxymethyl)aminomethane, phosphate buffer, borate buffer and Good's buffer.
  • Good's buffer are N-(2-acetamido)-2-aminoethanesulfonic acid (ACES), N-(2-acetamido)iminodiacetic acid (ADA), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 3-[N,N-bis(2-hydroxyethyl) amino]-2-hydroxypropanesulfonic acid (DIPSO), N-(2-hydroxyethyl)piperazine-N′-2-ethanesulfonic acid (HEPES), 2-(N-morpholino)ethanesulfonic acid (MES), 3-(N-morpholino)propanesulfonic acid (MOPS), 3-(N-morpholino)-2-hydroxypropanesulfonic acid (MOPSO), piperazine-N,N′-
  • the pH of the buffer solution is 4 to 10, preferably 5 to 9.
  • the concentration of the buffer is preferably 5 to 500 mM, more preferably 10 to 200 mM, particularly preferably 20 to 100 mM.
  • cholesterol esterase any enzyme capable of hydrolyzing cholesterol ester can be used. Suitable enzymes include cholesterol esterases and lipoprotein lipases derived from microorganisms and animals.
  • any enzyme capable of oxidizing cholesterol to form hydrogen peroxide can be used. Suitable enzymes include cholesterol oxidases derived from microorganisms and animals.
  • any enzyme capable of oxidizing cholesterol and reducing an oxidized coenzyme can be used.
  • Suitable enzymes include cholesterol dehydrogenases derived from microorganisms and animals.
  • enzymes may be chemically modified with a group having polyethylene glycol as a main component, a water-soluble oligosaccharide residue, a sulfopropyl group, or the like. Enzymes obtained by recombinant DNA techniques can also be used.
  • the respective concentration of cholesterol esterase, cholesterol oxidase and cholesterol dehydrogenase in a reaction mixture is preferably 0.01 to 200 U/ml, more preferably 0.1 to 100 U/ml.
  • surfactants or cholic acids which are often used to activate cholesterol esterase, cholesterol oxidase and cholesterol dehydrogenase can additionally be used so far as they do not affect the specificity of the reaction.
  • various salts for solubilizing proteins such as globulin in a biological sample may be used.
  • Surfactants useful for activating cholesterol esterase, cholesterol oxidase and cholesterol dehydrogenase include anionic surfactants such as alkyl sulfonate (e.g., 1-pentasulfonate, 1-hexasulfonate, 1-heptasulfonate and 1-octasulfonate).
  • the surfactants are used at a concentration of 0 to 5%.
  • As the cholic acid, cholic acid, deoxycholic acid, taurocholic acid, chenodeoxycholic acid, etc. can be used at a concentration of 0 to 5%.
  • Examples of the salts are sodium chloride, sodium sulfate, potassium chloride, potassium sulfate, magnesium chloride, magnesium sulfate, magnesium acetate, lithium chloride, lithium sulfate, ammonium chloride, ammonium sulfate, magnesium nitrate and calcium nitrate.
  • the salts are used at a concentration of 0 to 100 mM.
  • phospholipase any enzyme capable of hydrolyzing phospholipids can be used. Suitable enzymes include phospholipases derived from animals, plants and microorganisms, for example, phospholipase D, phospholipase C and phospholipase A2.
  • the concentration of phospholipase in a reaction mixture is preferably 0.01 to 200 U/ml, more preferably 0.1 to 100 U/ml.
  • the reaction catalyzed by these enzymes results in the formation of hydrogen peroxide from oxygen.
  • the determination of the formed hydrogen peroxide can be carried out, for example, by forming a pigment using 4-aminoantipyrine and phenol, 4-aminoantipyrine and Trinder's reagent, or a highly sensitive chromogen, in the presence of peroxidase, and by measuring the absorbance of a reaction mixture colored by the formed pigment.
  • Suitable phenols are phenol, 4-chlorophenol, m-cresol and 3-hydroxy-2,4,6-triiodobenzoic acid (HTIB).
  • Trinder's reagents (General Catalog of Dojin Kagaku Kenkyusho, 19th ed., 1994) are anilines such as N-sulfopropylaniline, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine (TOOS), N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline (MAOS), N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (DAOS), N-ethyl-N-sulfopropyl-m-toluidine (TOPS), N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (HDAOS), N,N-dimethyl-m-toluidine, N,N-disulfopropyl-3,5-dimethoxyaniline
  • Examples of the highly sensitive chromogens are 10-(N-methylcarbamoyl)-3,7-bis(dimethylamino)phenothiadine (MCDP) disclosed in Japanese Published Examined Patent Application No. 33479/85, bis[3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl] amine (BCMA) disclosed in Japanese Published Examined Patent Application No. 27839/92, and the compound disclosed in Japanese Published Unexamined Patent Application No. 296/87.
  • MCDP 10-(N-methylcarbamoyl)-3,7-bis(dimethylamino)phenothiadine
  • BCMA bis[3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl] amine
  • the concentration of these phenols, 4-aminoantipyrine, Trinder's reagents and highly sensitive chromogens is preferably 0.01 to 10 mg/ml.
  • NAD(P)H When a combination of cholesterol esterase and cholesterol dehydrogenase is used, the reaction catalyzed by these enzymes results in the formation of NAD(P)H, which is a reduced coenzyme, from NAD(P), which is an oxidized coenzyme.
  • the formed NAD(P)H can be determined by measuring the absorbance of a reaction mixture at 300 to 500 nm, preferably 330 to 400 nm, particularly preferably ca. 340 nm.
  • the determination of NAD(P)H can also be carried out by forming a formazan pigment by addition of diaphorase and a tetrazolium salt and then determining the formazan pigment by colorimetry.
  • the enzymatic reactions are carried out at 10 to 50° C., preferably 30 to 40° C., usually 37° C., for 1 to 30 minutes, preferably 2 to 10 minutes.
  • the invention is applicable to blood and blood fractions such as plasma and serum.
  • a surfactant which inhibits the action of cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase on cholesterol in lipoproteins other than remnant-like particles, alone or in combination with the above-mentioned surfactant which activates cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase.
  • This surfactant may be added when the biological sample is contacted with (i) cholesterol esterase, (ii) cholesterol oxidase or cholesterol dehydrogenase, and (iii) phospholipase, together with these enzymes, but is preferably added to the biological sample prior to the contact with these enzymes.
  • any surfactant can be used that reduces the action of cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase on cholesterol in lipoproteins other than remnant-like particles.
  • Useful surfactants include polyoxyalkylene derivatives and polyoxyethylene-polyoxypropylene copolymers or derivatives thereof.
  • Suitable polyoxyalkylene derivatives include polyoxyethylene alkyl ether, polyoxyethylenestyrenated phenyl ether and polyoxyethylene long-chain branched alkyl ether.
  • the alkyl in these derivatives includes alkyl having 8 or more carbon atoms such as octyl and nonyl.
  • polyoxyalkylene derivatives examples include commercially available polyoxyethylene alkyl ethers such as Nonion HS-210, Nonion HS-215, Nonion HS-208.5 and Nonion HS-208 (all produced by NOF Corporation) and Emulgen L-40, Emulgen 911 and Emulgen 810 (all produced by Kao Corporation), commercially available polyoxyethylenestyrenated phenyl ethers such as BLAUNON TSP-50 (Aoki Yushi Co., Ltd.), and commercially available polyoxyethylene long-chain branched alkyl ethers such as Unilube MT0620B (NOF Corporation).
  • polyoxyethylene alkyl ethers such as Nonion HS-210, Nonion HS-215, Nonion HS-208.5 and Nonion HS-208 (all produced by NOF Corporation) and Emulgen L-40, Emulgen 911 and Emulgen 810 (all produced by Kao Corporation
  • polyoxyethylenestyrenated phenyl ethers such as B
  • the hydrophile-lipophile balance (hereinafter referred to as HLB) of the polyoxyalkylene derivatives is preferably 9 to 20.
  • the polyoxyethylene-polyoxypropylene copolymers include random copolymers and block copolymers of polyoxyethylene and polyoxypropylene.
  • An example of the copolymer is a compound represented by general formula (I):
  • the straight-chain or branched alkyl is preferably alkyl having 1 to 30 carbon atoms, more preferably alkyl having 2 to 24 carbon atoms.
  • Examples of the compounds represented by general formula (I) include commercially available ones such as Pullulonic L-121, Pullulonic L-122, Pullulonic L-101, Pullulonic P-103 and Pullulonic F-108 (all produced by Asahi Denka Kogyo Co. Ltd.).
  • the molecular weight of the polypropylene glycol group in the compounds represented by general formula (I) is preferably 2050 or more, more preferably 2750 or more, particularly preferably 3250 or more.
  • the HLB of the polyoxyethylene-polyoxypropylene copolymers is preferably 1 to 6.
  • the concentration of the surfactant which inhibits the action of cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase on cholesterol in lipoproteins other than remnant-like particles is not specifically limited, but is preferably 0.001 to 10%, more preferably 0.01 to 5%, particularly preferably 0.05 to 1%.
  • the reaction mixture may further comprise a lipoprotein coagulant, an additional enzyme, etc., if necessary.
  • lipoprotein coagulant examples include polyanions such as phosphorus wolframate, dextran sulfate and heparin, and salts of divalent metals such as magnesium, calcium and cobalt.
  • additional enzyme is ascorbate oxidase.
  • Reagent 1 Good's buffer pH 6.8 (MOPS, Dojin Kagaku 20 mM Co., Ltd.) TOOS (Dojin Kagaku Co., Ltd.) 0.3 g/l Sodium sulfate 2 g/l Pullulonic F-108 (Asahi Denka Kogyo Co., Ltd.) 1 g/l Peroxidase (POD, Toyobo Co., Ltd.) 10 U/ml Ascorbate oxidase (AOD, Asahi Chemical 2 U/ml Industry Co., Ltd.)
  • Reagent 2 Reagent 2 Good's buffer pH 6.8 MOPS, Dojin Kagaku 20 mM Co., Ltd.
  • 4-Aminoantipyrine Nacalai Kagaku Co., Ltd.
  • 0.5 g/l Emulgen L-40 Kao Corporation
  • 2 g/l Peroxidase Toyobo Co., Ltd.
  • 10 U/ml Cholesterol esterase CEBP, Asahi Chemical 1 U/ml Industry Co., Ltd.
  • Cholesterol oxidase Kyowa Hakko Kogyo 2 U/ml Co., Ltd.
  • Phospholipase D Asahi Chemical Industry 5 U/ml Co., Ltd.
  • Reagent 1 of Example 1 (2.25 ml) was put into a cell of a spectrophotometer and 30 ⁇ l of a serum was added thereto, followed by stirring and then heating at 37° C. for 5 minutes.
  • To the cell was added 0.75 ml of Reagent 2 of Example 1 previously heated to 37° C., followed by stirring and then heating for 5 minutes.
  • the change in absorbance at 555 nm was measured.
  • the same procedure was repeated using a standard serum solution having a concentration of cholesterol in remnant-like particles of 49.6 mg/dl as determined by the RLP-C determination kit of Japan Antibody Institute to prepare a calibration curve. The concentration of cholesterol in remnant-like particles in the sample was determined from the above change in absorbance.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US09/788,393 2000-02-28 2001-02-21 Method and reagent for determination of cholesterol in remant-like particles Abandoned US20010031479A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/430,231 US7202047B2 (en) 2000-02-28 2003-05-06 Aqueous method for determining cholesterol in remnant-like particles using cholesterol esterase, phospholipase, surfactant and cholesterol oxidase or dehydrogenase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-050902 2000-02-28
JP2000050902A JP4456715B2 (ja) 2000-02-28 2000-02-28 レムナント様リポ蛋白中のコレステロールの測定方法および測定試薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/430,231 Continuation US7202047B2 (en) 2000-02-28 2003-05-06 Aqueous method for determining cholesterol in remnant-like particles using cholesterol esterase, phospholipase, surfactant and cholesterol oxidase or dehydrogenase

Publications (1)

Publication Number Publication Date
US20010031479A1 true US20010031479A1 (en) 2001-10-18

Family

ID=18572634

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/788,393 Abandoned US20010031479A1 (en) 2000-02-28 2001-02-21 Method and reagent for determination of cholesterol in remant-like particles
US10/430,231 Expired - Lifetime US7202047B2 (en) 2000-02-28 2003-05-06 Aqueous method for determining cholesterol in remnant-like particles using cholesterol esterase, phospholipase, surfactant and cholesterol oxidase or dehydrogenase

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/430,231 Expired - Lifetime US7202047B2 (en) 2000-02-28 2003-05-06 Aqueous method for determining cholesterol in remnant-like particles using cholesterol esterase, phospholipase, surfactant and cholesterol oxidase or dehydrogenase

Country Status (7)

Country Link
US (2) US20010031479A1 (fr)
EP (1) EP1132482B1 (fr)
JP (1) JP4456715B2 (fr)
AT (1) ATE239800T1 (fr)
AU (1) AU2324301A (fr)
CA (1) CA2337559C (fr)
DE (1) DE60100241T2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161068A1 (en) * 2004-01-29 2007-07-12 Kyowa Medex Co., Ltd. Method, reagent and kit for determination of cholesterol in very low-density lipoprotein remnant (vldl remnant)
US20090023167A1 (en) * 2005-02-14 2009-01-22 Kyowa Medex Co., Ltd. Method, reagent and kit for determination of cholesterol in remnant-like particles (rlp)
US20090170139A1 (en) * 2005-12-09 2009-07-02 Kyowa Medex Co., Ltd. Method, reagent and kit for measurement of cholesterol in remnant-like particles
US20130288281A1 (en) * 2007-10-10 2013-10-31 Denka Seiken Co., Ltd. Method and kit for quantitatively determining small, dense ldl cholesterol
CN109312389A (zh) * 2016-05-24 2019-02-05 电化生研株式会社 富含甘油三酯的脂蛋白中的胆固醇的定量方法以及定量试剂
CN111337440A (zh) * 2018-12-18 2020-06-26 上海底物生化科技有限公司 一种心脑血管事件风险筛查的试剂盒及其检测方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003301324A1 (en) * 2002-10-16 2004-05-04 Kyowa Medex Co., Ltd. Method and reagent for measuring cholesterol in high-density lipoproteins
CA2507725A1 (fr) 2002-11-27 2004-06-10 Daiichi Pure Chemicals Co., Ltd. Mesure d'un lipide dans une lipoproteine specifique
JP4647927B2 (ja) * 2004-03-31 2011-03-09 デンカ生研株式会社 低密度リポ蛋白中コレステロールのマルチ定量法
CA2589459C (fr) * 2004-11-29 2014-01-07 Jimro Co., Ltd. Procede de mesure du cholesterol dans des lipoproteines du type residuelles
EP1930442B1 (fr) * 2005-08-31 2010-11-03 DENKA SEIKEN Co., Ltd. Methode et necessaire pour quantifier le small, dense ldl cholesterol
EP1953240A4 (fr) 2005-10-31 2009-08-26 Kyowa Medex Co Ltd Procede de mesure de triglyceride dans une lipoproteine de basse densite et kit de mesure
CA2636492A1 (fr) * 2006-01-20 2007-07-26 Jimro Co., Ltd Procede de mesure du cholesterol dans une lipoproteine de type residuelle
JP5766426B2 (ja) 2010-11-10 2015-08-19 デンカ生研株式会社 レムナント様リポ蛋白コレステロールの定量方法及びそのためのキット
EP2751575B1 (fr) 2011-11-11 2018-09-12 Axis-Shield AS Procédé de dosage d'échantillon de sang
JP7134667B2 (ja) * 2018-03-28 2022-09-12 デンカ株式会社 リポ蛋白コレステロールの定量方法、定量試薬及び定量キット
CN109706218A (zh) * 2019-03-08 2019-05-03 浙江达美生物技术有限公司 一种测定脂蛋白残粒胆固醇的试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555173A (en) * 1977-08-17 1979-11-07 Kyowa Hakko Kogyo Kk Method and reagent for quantitative determination of phospholipids
DE3319066A1 (de) 1983-05-26 1984-11-29 Claus-Christian Dr.Rer.Nat. Dr.Med. 6901 Wilhelmsfeld Heuck Verfahren und reagenz zum direkten nachweis eines analyts nach spezifischer entfernung von colloidpartikeln in waessrigen loesungen biologischer herkunft
JPH07121901B2 (ja) 1986-07-01 1995-12-25 和光純薬工業株式会社 新規な尿素誘導体及びこれを発色成分として用いる測定法
US5164512A (en) 1989-06-21 1992-11-17 Wako Pure Chemical Industries, Ltd. Oxidizable color producing reagent
JP2701090B2 (ja) 1990-11-30 1998-01-21 和光純薬工業株式会社 被酸化性呈色試薬
DK0670367T3 (da) 1993-05-19 2003-11-24 Kao Corp Flydendegørende alkalisk alfa-amylase, fremgangsmåde til fremstilling af denne og detergentsammensætning indeholdende denne
JP2653755B2 (ja) * 1994-03-08 1997-09-17 協和メデックス株式会社 高密度リポ蛋白中のコレステロールの定量法
JP2600065B2 (ja) * 1994-03-08 1997-04-16 協和メデックス株式会社 高密度リポ蛋白中のコレステロールの定量法
WO1996029599A1 (fr) * 1995-03-20 1996-09-26 Kyowa Medex Co., Ltd. Methode de quantification du cholesterol dans une lipoproteine a faible densite ou a tres faible densite
JPH08105875A (ja) * 1994-08-12 1996-04-23 Tosoh Corp リポタンパク質分離用充填剤、その充填剤を充填してなる抗体カラム及びそのカラムを用いたレムナント様リポタンパク質の分析方法
JPH08105876A (ja) * 1994-08-12 1996-04-23 Tosoh Corp レムナント様リポタンパク質の分析方法
JP3256241B2 (ja) * 1995-03-16 2002-02-12 協和メデックス株式会社 低密度リポ蛋白中のコレステロールの定量法
US6114134A (en) * 1997-06-25 2000-09-05 International Reagents Corporation Method for assaying biological specimens for substances contained in the components thereof and reagent to be used in this method
JP3251304B2 (ja) * 1997-06-25 2002-01-28 国際試薬株式会社 生体試料成分中の物質の分析方法及びこれに用いられる試薬
ATE278805T1 (de) * 1998-09-18 2004-10-15 Kyowa Medex Co Ltd Verfahren zur quantifizierung von cholesterol in lipoproteinen und quantifizierungsreagenzien
US6986998B2 (en) * 2000-06-07 2006-01-17 International Reagents Corporation Method of analyzing components in biological samples

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161068A1 (en) * 2004-01-29 2007-07-12 Kyowa Medex Co., Ltd. Method, reagent and kit for determination of cholesterol in very low-density lipoprotein remnant (vldl remnant)
US20090023167A1 (en) * 2005-02-14 2009-01-22 Kyowa Medex Co., Ltd. Method, reagent and kit for determination of cholesterol in remnant-like particles (rlp)
US8119360B2 (en) * 2005-02-14 2012-02-21 Kyowa Medex Co., Ltd. Method, reagent and kit for determination of cholesterol in remnant-like particles (RLP)
KR101326476B1 (ko) * 2005-02-14 2013-11-07 교와 메덱스 가부시키가이샤 렘난트형 리포단백질 (ｒｌｐ) 중의 콜레스테롤의 정량방법, 시약 및 키트
US20090170139A1 (en) * 2005-12-09 2009-07-02 Kyowa Medex Co., Ltd. Method, reagent and kit for measurement of cholesterol in remnant-like particles
US20130288281A1 (en) * 2007-10-10 2013-10-31 Denka Seiken Co., Ltd. Method and kit for quantitatively determining small, dense ldl cholesterol
US8865423B2 (en) * 2007-10-10 2014-10-21 Denka Seiken Co., Ltd. Method and kit for quantitatively determining small, dense LDL cholesterol
CN109312389A (zh) * 2016-05-24 2019-02-05 电化生研株式会社 富含甘油三酯的脂蛋白中的胆固醇的定量方法以及定量试剂
CN111337440A (zh) * 2018-12-18 2020-06-26 上海底物生化科技有限公司 一种心脑血管事件风险筛查的试剂盒及其检测方法

Also Published As

Publication number Publication date
EP1132482A3 (fr) 2001-09-26
EP1132482A2 (fr) 2001-09-12
US7202047B2 (en) 2007-04-10
CA2337559C (fr) 2009-10-13
DE60100241D1 (de) 2003-06-12
JP4456715B2 (ja) 2010-04-28
JP2001231597A (ja) 2001-08-28
CA2337559A1 (fr) 2001-08-28
EP1132482B1 (fr) 2003-05-07
ATE239800T1 (de) 2003-05-15
AU2324301A (en) 2001-08-30
DE60100241T2 (de) 2004-02-19
US20030207342A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
US6794157B1 (en) Methods for fractional quatification of cholesterol in lipoproteins and quantification reagents
US7202047B2 (en) Aqueous method for determining cholesterol in remnant-like particles using cholesterol esterase, phospholipase, surfactant and cholesterol oxidase or dehydrogenase
FI83975B (fi) Foerfarande och reagens foer specifik bestaemning av hdl-kolesterolhalt i serum.
US8178311B2 (en) Multiple quantification of cholesterol in low density lipoprotein
WO2008050636A1 (fr) Procédé de quantification du cholestérol dans une lipoprotéine de faible densité
WO2004035816A1 (fr) Procede et reactif permettant de mesurer le cholesterol dans des lioproteines a densite elevee
US20090170139A1 (en) Method, reagent and kit for measurement of cholesterol in remnant-like particles
US8765394B2 (en) Method of quantifying cholesterol in high density lipoprotein and reagent compositions
KR20150003739A (ko) 검체 중의 측정 대상 성분의 측정 방법
US20040265939A1 (en) Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same
CN111032880A (zh) 低密度脂蛋白中的胆固醇的测定方法、测定用试剂和测定用试剂盒
US6986998B2 (en) Method of analyzing components in biological samples
EP1818412B1 (fr) Procede de mesure du cholesterol dans des lipoproteines du type residuelles
US20080318258A1 (en) Method for Measuring Cholesterol in Remnant-Like Lipoprotein
US20130230873A1 (en) Method for quantification of remnant-like lipoprotein cholesterol and kit for same
US20140147869A1 (en) Method and Kit for Measuring Cholesterol in Low-Density Lipoproteins
JP3446486B2 (ja) リポタンパク中の成分の測定法
KR20140001996A (ko) Hdl 소분획 중의 콜레스테롤의 측정 방법, 측정용 시약 및 측정용 키트
JPH11103888A (ja) 生体成分測定用試薬および測定方法
EP2987867B1 (fr) Procédé de mesure de l'activité de la lipase pancréatique humaine
JP2001224397A (ja) 低密度リポ蛋白中のコレステロールの定量方法
JP2007014201A (ja) レムナント様リポタンパク質中のコレステロールの測定方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: KYOWA MEDEX CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MIYAUCHI, KAZUHITO;REEL/FRAME:011576/0516

Effective date: 20010209

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION